Key result
Warfarin shows poor INR control in ~43% of non-valvular AF patients by NICE criteria.
Why the study?
The study aimed to quantify patients with non-valvular atrial fibrillation on warfarin who had poor INR control by NICE criteria and identify associated clinical characteristics.
Observational (n=32,380)
Answers are grounded in this paper and cite their sources.
Relying solely on Time in Therapeutic Range (TTR) to assess warfarin effectiveness misses a significant proportion of patients with dangerously out-of-range INRs.
AIMS: In patients with non-valvular atrial fibrillation prescribed warfarin, the UK National Institute of Health and Care Excellence (NICE) defines poor anticoagulation as a time in therapeutic range (TTR) of <65%, any two international normalized ratios (INRs) within a 6-month period of ≤1.5 ('low'), two INRs ≥5 within 6 months, or any INR ≥8 ('high'). Our objectives were to (i) quantify the number of patients with poor INR control and (ii) describe the demographic and clinical characteristics associated with poor INR control. METHOD AND RESULTS: Linked anonymized health record data for Wales, UK (2006-2017) was used to evaluate patients prescribed warfarin who had at least 6 months of INR data. 32 380 patients were included. In total, 13 913 (43.0%) patients had at least one of the NICE markers of poor INR control. Importantly, in the 24 123 (74.6%) of the cohort with an acceptable TTR (≥65%), 5676 (23.5%) had either low or high INR readings at some point in their history. In a multivariable regression female gender, age (≥75 years), excess alcohol, diabetes heart failure, ischaemic heart disease, and respiratory disease were independently associated with all markers of poor INR control. CONCLUSION: Acceptable INR control according to NICE standards is poor. Of those with an acceptable TTR (>65%), one-quarter still had unacceptably low or high INR levels according to NICE criteria. Thus, only using TTR to assess effectiveness with warfarin has the potential to miss a large number of patients with non-therapeutic INRs who are likely to be at increased risk.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2019) conducted an observational in non-valvular atrial fibrillation (n=32,380). Warfarin was evaluated on Poor INR control according to NICE criteria. Among patients with non-valvular atrial fibrillation prescribed warfarin, 43.0% had poor INR control according to NICE criteria, and 23.5% of those with acceptable TTR had out-of-range INRs.
Synapse has enriched 10 related papers. Consider them for comparative context: